Q2 2026 Ashland Inc Earnings Call Transcript
Key Points
- Ashland Inc (ASH) reported resilient underlying commercial performance amid stable demand conditions, with a focus on pricing and portfolio mix actions.
- Life Sciences segment delivered steady results, supported by resilient pharmaceutical demand, marking a fourth consecutive quarter of volume gains.
- Personal Care segment generated broad-based portfolio growth, driven by strong volume gains and execution across biofunctional actives, care ingredients, and microbial protection.
- Specialty Additives segment saw coatings volumes grow year-over-year, reflecting share gains and new product traction.
- The company demonstrated strong cash flow management, with operating cash flow increasing significantly due to disciplined working capital management.
- Adjusted EBITDA was down 9% year-over-year, impacted by temporary issues such as the Calvert City start-up delay and weather-related operational disruptions.
- Adjusted EBITDA margin decreased by 220 basis points year-over-year, largely due to temporary operational disruptions.
- Intermediates segment operated in a challenging market environment, with sales and pricing at trough levels across the BDO value chain.
- Specialty Additives segment faced softer pricing and higher manufacturing-related costs, including weather-related disruptions and productivity challenges.
- The company lowered its fiscal 2026 sales guidance due to softer energy-related demand tied to the Middle East conflict and reduced EV-driven demand.
Good day, and thank you for standing by. Welcome to Ashland's second quarter 2026 earnings call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Sandy Klugman, Director of Investor Relations. Please go ahead.
Thank you. Hello, everyone, and welcome to Ashland's Second Quarter Fiscal 2026 Earnings Conference Call and Webcast. My name is Sandy Klugman, and I am Ashland's Director of Investor Relations. Joining me on the call today are Guillermo Novo, Chair and CEO; William Whitaker, CFO; as well as our business unit leaders; Alessandra Assis, Life Sciences and Intermediates; Jim Minicucci, Personal Care; and Dago Caceres, Specialty Additives. Please note that we will be referencing slides during today's call. We encourage you to follow along with the webcast materials available at ashland.com under Investor Relations. Please turn to Slide 2.
As a reminder, today's presentation contains
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
